[ad_1]
ILLUSTRATION. According to preliminary data from the final stage of the trial in Turkey, the Covid-19 vaccine developed by Sinovac Biotech China is 91.25% effective. REUTERS / Tingshu Wang
Source: Reuters | Editor: Barratut Taqiyyah Rafie
KONTAN.CO.ID – ANKARA. According to preliminary data from the final stage of the trial in Turkey, the Covid-19 vaccine developed by Sinovac Biotech China is 91.25% effective. These results are potentially much better than those reported in separate vaccine trials in Brazil.
Reuters According to the report, the Brazilian researchers, who are also running the final phase III trial of the vaccine, said Wednesday that the injection was more than 50% effective. However, Brazil withheld full performance at the company’s request, raising questions about transparency.
Turkish researchers said on Thursday (12/24/2020) that no major side effects were observed during their experiment, other than that one person had an allergic reaction. Common side effects caused by the vaccine are fever, mild pain and mild fatigue, they said.
According to the researchers, the Turkish trial started on September 14 and has involved more than 7,000 volunteers. They added that the results announced Thursday were based on data from 1,322 people.
Read also: Epidemiologists mention a group that cannot be injected with the Covid-19 vaccine
Sinovac is the first Chinese vaccine manufacturer to publish details of an end-stage clinical trial, following positive results from rival products developed by Pfizer, Moderna and AstraZeneca last month.
Turkish researchers, speaking with Health Minister Fahrettin Koca, said that 26 of the 29 people infected during the trial received a placebo. They added that the trials will continue until 40 people are infected.
Read also: Kalbe Farma (KLBF) is preparing for a phase 2 clinical trial of the Covid-19 vaccine in the first quarter of 2021
“We are now confident that the vaccine is effective and safe (to use) for the Turkish people,” Koca said, adding that Ankara would use the data to authorize the vaccine.
